Retrospective Assessment of the Use of Pharmacotherapeutic Agents in Pregnancy with Potential Impact on Neonatal Health

European Pharmaceutical Journal

article

K. Podolská¹  D. Mazánková¹  M. Göböová² 

[1] Department of Applied Pharmacy, Faculty of Pharmacy, Masaryk University;Department of Internal Medicine, Teaching Hospital Nitra

关键词: pregnancy;    clinical pharmacist;    foetal risk;    safety of therapeutic agents;    teratogenicity;   

DOI  :  10.2478/afpuc-2022-0015

学科分类：社会科学、人文和艺术（综合）

来源: Walter de Gruyter GmbH

【 摘 要 】

This study focuses on the role of a clinical pharmacist in the optimisation of pharmacotherapy in the case of patients during pregnancy and its importance within the hospital sector in Slovakia. Retrospective evaluation of pharmacotherapy in pregnant patients with a focus on teratogenicity and appropriate drug selection was used. The hospital data were collected during 24 months from 22 female patients. The main observed outcome was health condition of the newborn, and it was expressed as healthy newborn, illness of the newborn, any congenital defect or malformation, spontaneous abortion, or unspecified information about the newborn. Based on a foetal risk assessment of used therapeutic agents from the Summary of Product Characteristics (SmPC), basal foetal and neonatal risk assessment (Briggs et al., 2017), and recommendations and related human past reports and supporting evidence studies, drugs were divided into two groups: confirmed foetal risk drugs and negative (nonconfirmed) foetal risk drugs. A total of 36.3% of the patients used two drugs. Patients most frequently used drugs during the first trimester (81.8%). During pregnancy, the most used drugs were for the nervous system (25.5%), anti-infective agents (23.6%), and respiratory therapeutic agents (14.5%).

【 授权许可】

CC BY-NC-ND